TARO-SIMVASTATIN 80 MG
SIMVASTATIN : 80 MG · DIN 02329182 · SUN PHARMA CANADA INC
Health Canada status: MARKETED
What is TARO-SIMVASTATIN?
TARO-SIMVASTATIN 80 MG contains SIMVASTATIN : 80 MG. It is listed in the Health Canada Drug Product Database under DIN 02329182, held by SUN PHARMA CANADA INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 20-Jan-2020. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is TARO-SIMVASTATIN used for?
TARO - SIMVASTATIN (simvastatin) is indicated in adults as an adjunct to diet for: Reduction of risk of total mortality, myocardial infarction and ischemic stroke in patients with high risk of coronary events (because of existing Coronary Heart Disease (CHD), occlusive arterial disease, or diabetic over the age of 40) regardless of their lipid status. Slowing progression of coronary atherosclerosis, including reducing the development of new lesions and new total occlusions in hypercholesterolemic patients with CHD. Reduction of elevated total cholesterol (total - C) and Low - Density Lipoprotein - cholesterol (LDL - C), apolipoprotein B (apo B), and triglycerides (TG) levels in patients with primary hypercholesterolemia (Type IIa) or combined (mixed) hyperlipidemia (Type II b). In pediatric patients with heterozygous familial hypercholesterolemia (10 - <18 years of age), TARO - SIMVASTATIN is indicated as an adjunct to diet to reduce total - C, LDL - C, TG, and Apo B levels.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02329182 |
|---|---|
| Brand name | TARO-SIMVASTATIN |
| Generic / active ingredient | SIMVASTATIN : 80 MG |
| Manufacturer | SUN PHARMA CANADA INC |
| Strength | 80 MG |
| Dosage form | TABLET |
| Route of administration | ORAL |
| Schedule | Prescription |
| ATC code | C10AA01 SIMVASTATIN |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 20-Jan-2020 |
How is it stored and handled?
null
How is it supplied?
HDPE bottles of 30s, 100s and 1000s and blister packages of 30 (3 x 10) tablets for 5 mg, 10 mg, 20 mg, 40 mg, and 80 mg tablets. HDPE bottles of 500s for 10 mg, 20 mg, and 40 mg tablets.
Is SIMVASTATIN in shortage in Canada?
A Canadian shortage report is on file for this molecule: Anticipated — reported by SANIS HEALTH INC, last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code C10AA01 SIMVASTATIN. 60 of 218 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-SIMVASTATIN | 10 MG | TABLET | APOTEX INC | MARKETED | DIN 02247012 |
| APO-SIMVASTATIN | 20 MG | TABLET | APOTEX INC | MARKETED | DIN 02247013 |
| APO-SIMVASTATIN | 40 MG | TABLET | APOTEX INC | MARKETED | DIN 02247014 |
| APO-SIMVASTATIN | 5 MG | TABLET | APOTEX INC | MARKETED | DIN 02247011 |
| APO-SIMVASTATIN | 80 MG | TABLET | APOTEX INC | MARKETED | DIN 02247015 |
| AURO-SIMVASTATIN | 10 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02405156 |
| AURO-SIMVASTATIN | 20 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02405164 |
| AURO-SIMVASTATIN | 40 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02405172 |
| AURO-SIMVASTATIN | 5 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02405148 |
| AURO-SIMVASTATIN | 80 MG | TABLET | AURO PHARMA INC | MARKETED | DIN 02405180 |
Who else supplies SIMVASTATIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. SIMVASTATIN appears in 8530 registered pack listings across 12 markets, published on 10 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.